ASTEC

Astec LifeSciences Financial Results

₹742.35+5.34%
Market cap
₹1,654 crore
P/E
22.5
P/B
4.23
ROE
-25.9%
Dividend yield
1.20%

For the year ended Mar 2019, Astec LifeSciences reported revenue of ₹431 crore and net profit of ₹36 crore, against ₹523 crore and ₹48 crore a year earlier.

Astec LifeSciences annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Astec LifeSciences annual profit and loss (₹ crore)
ItemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue431523555677628458378446438
Expenses354437443522551463444450432
Operating profit768511215477-5-66-46
Operating margin %18%16%20%23%12%-1%-17%-1%1%
Other income1112810125523
Interest1213592025363431
Depreciation192326343436444544
Profit before tax56618912135-62-141-81-67
Tax %36%23%27%26%27%24%4%0%0%
Net profit3648659026-47-135-81-67
EPS (₹)18.0924.0532.9345.4912.94-23.75-68.19-36.31-29.89
Dividend payout %—————————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Astec LifeSciences financial results — frequently asked questions

What is Astec LifeSciences' annual revenue and net profit?

For the financial year ended Mar 2019, Astec LifeSciences' revenue was ₹431 crore and net profit ₹36 crore; net profit fell 25.00% from ₹48 crore in Mar 2020.

How fast has Astec LifeSciences grown over three years?

From Mar 2022 to Mar 2019, Astec LifeSciences' revenue grew at a compound annual rate of -14.0% and net profit at -26.3%. Past growth does not indicate future results.

What is the EPS of Astec LifeSciences?

Annual EPS for Mar 2019 was ₹18.09.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Astec LifeSciences With ATS

Track ASTEC live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.